Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases

main

01_28 Quench Bio Closes 50 million Series A

Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases | News & Events | Goodwin

Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases

Related Content

FTC Issues Final Rule Prohibiting Most Post-Employment Non-Compete Agreements

The European Parliament Adopts Position on the European Commission’s Proposal for the First Major Overhaul of the EU Medicines Regulatory Framework in 20 Years

Recap: Goodwin Rare Disease Symposium 2024

FDA Approval of Alvotech/Teva Ustekinumab Biosimilar

DOJ Files False Claims Act Complaint Against Regeneron, Alleging Fraudulent Eylea Drug Pricing

Federal Circuit Dismisses Appeals in Regeneron v. Mylan (Aflibercept) BPCIA Litigation

The European Parliament Adopts Position on the European Commission’s Proposal for the First Major Overhaul of the EU Medicines Regulatory Framework in 20 Years

Fresenius Kabi Announces Launch of TYENNE, a Tocilizumab Biosimilar Referencing ACTEMRA

Allurion Technologies Completes $48 Million Convertible Senior Secured Note Financing with RTW Investments

Sound Bioventures joins £19 Million Financing of Theolytics

PowerUp 4 - Omer Tene (Spotify)

Goodwin is Number One in the Q1 2024 League Table Rankings

Lumicell’s Novel Optical Imaging Agent Platform LUMISIGHT™ & Direct Visualization System for Detection of Residual Breast Cancer Receives FDA Approval

Abingworth to Provide Teva with up to $150 Million in Financing to Advance Treatment of Asthma

Goodwin Represents the Underwriters in PACS Group $450 Million IPO

Goodwin Advises Exclusive Placement Agent in Acrivon Therapeutics’ $130 Million Private Placement

Life Sciences

Venture Capital